Important CV Risk Seen With Carfilzomib in Multiple Myeloma Important CV Risk Seen With Carfilzomib in Multiple Myeloma

Carfilzomib, approved for previously treated multiple myeloma, is associated with a significantly greater risk for all-grade and high-grade cardiovascular events and requires vigilance when used.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news